License Agreements (Details Narrative) - USD ($)							12 Months Ended
	May 17, 2022	Jun. 16, 2021	Oct. 06, 2020	Aug. 23, 2020	Aug. 19, 2020	Mar. 19, 2018	Dec. 31, 2022	Dec. 31, 2021
Stock Issued During Period, Value, New Issues								$ 9,875,550
CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member]
Shares issued in connection with license agreement						298,615
Stock Issued During Period, Value, New Issues						$ 8,000,000
Business Acquisition, Share Price						$ 26.79
License Agreement [Member] | Elion Oncology [Member]
Conditions for grant of license, description				The grant of license was conditioned on the following being satisfied by October 30, 2020: (i) our closing on an equity financing of at least $15 million in gross proceeds and (ii) successful up-listing to Nasdaq.
Cash paid under license agreement			$ 100,000
Shares issued in connection with license agreement			825,000				100,000	100,000
Common stock, lock-up description			Such shares were subject to a lock-up, with 50% of such shares released from such lock-up after six months and the remaining 25% tranches were released following 9 months and 12 months, respectively
Common Stock, Capital Shares Reserved for Future Issuance			100,000
Milestone payments, description			As additional consideration, we will pay Elion development and regulatory milestone payments (a portion of which are payable in shares of our common stock and a portion of which are payable in cash) upon the achievement of certain milestones, which include FDA or other regulatory approval and dosing a patient
Expense and related liability	$ 189,000
Performance of milestone conditions, description			specific diligence milestones that consist of: (i) dosing a first patient in a Phase 1B clinical trial with a product within 12 months; and (ii) dosing a first patient with a product in a Phase 2 or 3 clinical trial within 48 months. Either party may terminate the agreement in the event of a material breach of the agreement that has not been cured following written notice and a 90-day opportunity to cure such breach (which is shortened to 15 days for a payment breach).
License Agreement [Member] | Elion Oncology [Member] | First Milestone [Member]
Milestone payment description			shares of our common stock on each of the first and second anniversary dates of the Elion License Agreement, which we fulfilled on October 5, 2021 and 2022, respectively.
License Agreement [Member] | Ocuphire Pharma Inc [Member]
Cash paid under license agreement		$ 200,000
Shares issued in connection with license agreement		44,689
Liabilities assumed		$ 66,583
License Agreement [Member] | Aposense, Ltd. [Member]
Shares issued in connection with license agreement			625,000
Common stock, lock-up description			Such shares were subject to a lock-up, with 40% of such shares released from such lock-up after six months and the remaining two 30% tranches were released upon completion of the next two subsequent quarters
Milestone payments, description			As additional consideration, we will pay Aposense development and regulatory milestone payments (up to $3.0 million per milestone) upon the achievement of certain milestones, which primarily consist of having a drug indication approved by a regulatory authority in the United States or another country. In addition, we will pay Aposense one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any sales milestone payments or royalties we receive with Aposense based on any sub-license agreement we may enter into
License Agreement [Member] | Aposense, Ltd. [Member] | Maximum [Member]
Development and regulatory milestone payments			$ 3,000,000.0
License Agreement [Member] | Yuhan Corporation [Member]
Shares issued in connection with license agreement					500,000
Milestone payments, description					In addition, we must pay Yuhan one-time sales milestone payments based on the achievement during a calendar year of one or more thresholds for annual sales for products made and pay royalties based on annual licensing sales. We are also required to split any milestone payments received with Yuhan based on any sub-license agreement we may enter into
Performance of milestone conditions, description					specific diligence milestones that consist of: (i) preparing a first draft of the product development plan within 90 days; (ii) requesting an FDA pre-IND meeting for a product within 6 months; (iii) dosing a first patient in a Phase 2A clinical trial with a product within 24 months; and (iv) dosing a first patient with a product in a Phase 2B clinical trial, Phase 3 clinical trial or other pivotal clinical trial with a product within 48 months
License Agreement [Member] | Yuhan Affiliate [Member] | Underwritten Public Offering [Member] | October 2020 [Member]
Shares issued in connection with our 2020 offering			750,000
Proceeds from offering			$ 3,000,000